A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

NCT05651711 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
726
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Amgen